ARVINAS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.27 USD | +1.06% |
|
+5.46% | -14.32% |
| Apr. 15 | H.C. Wainwright Cuts Price Target on Arvinas to $87 From $90, Maintains Buy Rating | MT |
| Apr. 12 | HC Wainwright Adjusts Arvinas' Price Target to $87 From $90, Keeps Buy Rating | MT |
Financials (USD)
| Sales 2024 * | 161M | Sales 2025 * | 217M | Capitalization | 2.38B |
|---|---|---|---|---|---|
| Net income 2024 * | -327M | Net income 2025 * | -336M | EV / Sales 2024 * | 9.78 x |
| Net cash position 2024 * | 814M | Net cash position 2025 * | 444M | EV / Sales 2025 * | 8.94 x |
| P/E ratio 2024 * |
-6.81
x | P/E ratio 2025 * |
-6.68
x | Employees | 445 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Arvinas, Inc.
More recommendations
More press releases
More news
| 1 day | +0.52% | ||
| 1 week | +0.52% | ||
| Current month | -15.46% | ||
| 1 month | -16.71% | ||
| 3 months | -4.51% | ||
| 6 months | +135.33% | ||
| Current year | -15.21% |
1 week
32.61
35.87
1 month
32.6142.26
Current year
32.6153.08
1 year
13.5753.08
3 years
13.57108.47
5 years
13.57108.47
10 years
10.19108.47
| Managers | Title | Age | Since |
|---|---|---|---|
John Houston
CEO | Chief Executive Officer | 64 | 16-12-31 |
Randy Teel
DFI | Director of Finance/CFO | 45 | 18-04-30 |
Lisa Sinclair
COO | Chief Operating Officer | - | 22-08-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wendy Dixon
BRD | Director/Board Member | 68 | 20-06-28 |
John Young
BRD | Director/Board Member | 60 | 22-08-17 |
Leslie Norwalk
BRD | Director/Board Member | 58 | 19-07-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 27 M€ | -5.28% | - | |
| 0.21% | 0 M€ | 0.00% | - | |
| 0.15% | 0 M€ | 0.00% | - | |
| 0.11% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 35.31 | +1.17% | 81 246 |
| 24-04-22 | 34.9 | +0.52% | 848,812 |
| 24-04-19 | 34.72 | +1.25% | 944,327 |
| 24-04-18 | 34.29 | +2.51% | 803,276 |
| 24-04-17 | 33.45 | +0.03% | 516,210 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Calendar
2024-04-29
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
34.9
USD
Average target price
70.83
USD
Spread / Average Target
+102.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.21% | 2.38B | |
| +2.49% | 96.73B | |
| -0.38% | 21.31B | |
| -16.61% | 21.21B | |
| -4.97% | 18.79B | |
| -42.14% | 16.37B | |
| -27.40% | 13.68B | |
| +1.44% | 13.44B | |
| +21.29% | 10.98B | |
| -21.79% | 8.56B |
- Stock Market
- Equities
- ARVN Stock
